Weiner Joshua, Griesemer Adam, Island Eddie, Lobritto Steven, Martinez Mercedes, Selvaggi Gennaro, Lefkowitch Jay, Velasco Monica, Tryphonopoulos Panagiotis, Emond Jean, Tzakis Andreas, Kato Tomoaki
Center for Liver Disease and Transplantation, New York Presbyterian-Columbia University Medical Center, New York, NY.
Division of Transplant Surgery, MedStar Georgetown University Hospital, Washington, DC.
Liver Transpl. 2016 Apr;22(4):485-94. doi: 10.1002/lt.24361.
By preserving part of the native liver, auxiliary partial orthotopic liver transplantation (APOLT) provides the advantage of potential immunosuppression (ISP) withdrawal if the native liver recovers but has had limited acceptance, especially in the United States, due to technical complications and low rates of native liver regeneration. No previous study has evaluated APOLT specifically for preadolescent children with fulminant hepatic failure (FHF). This population might benefit especially based on greater capacity for liver regeneration. Data from 13 preadolescent children who underwent APOLT were compared to 13 matched controls who underwent orthotopic liver transplantation (OLT) for FHF from 1996 to 2013. There were no significant differences in patient demographics or survival between the 2 groups. However, all surviving OLT recipients (10/13) remain on ISP, while all but 1 surviving APOLT recipient (12/13) showed native liver regeneration, and the first 10 recipients (76.9%) are currently off ISP with 2 additional patients currently weaning. In our experience, APOLT produced excellent survival and high rates of native liver regeneration in preadolescent children with FHF. This represents the largest series to date to report such outcomes. Liberating these children from lifelong ISP without the downside of increased surgical morbidity makes APOLT an attractive alternative. In conclusion, we therefore propose that, with the availability of technical expertise and with the technical modifications above, APOLT for FHF should be strongly considered for preteenage children with FHF.
通过保留部分自体肝脏,辅助性部分原位肝移植(APOLT)具有潜在的免疫抑制撤减优势,即如果自体肝脏恢复功能,就可以撤减免疫抑制,但由于技术并发症和自体肝脏再生率低,该方法的接受度有限,在美国尤其如此。此前尚无研究专门评估APOLT用于青春期前暴发性肝衰竭(FHF)儿童的情况。鉴于该人群肝脏再生能力更强,可能会特别受益。将1996年至2013年间接受APOLT的13例青春期前儿童的数据与13例因FHF接受原位肝移植(OLT)的匹配对照进行比较。两组患者的人口统计学特征或生存率无显著差异。然而,所有存活的OLT受者(10/13)仍在接受免疫抑制治疗,而除1例存活的APOLT受者外(12/13),其余所有受者均出现了自体肝脏再生,前10例受者(76.9%)目前已停用免疫抑制治疗,另有2例患者正在逐渐减停。根据我们的经验,APOLT在青春期前FHF儿童中产生了优异的生存率和高自体肝脏再生率。这是迄今为止报告此类结果的最大系列研究。将这些儿童从终身免疫抑制治疗中解放出来,且没有增加手术并发症的弊端,使得APOLT成为一个有吸引力的选择。总之,我们因此建议,鉴于技术专业知识的可得性以及上述技术改进,对于患有FHF的青春期前儿童,应强烈考虑采用APOLT治疗FHF。